Edition:
United Kingdom

Pfizer Inc (PFE.N)

PFE.N on New York Stock Exchange

41.85USD
22 Mar 2019
Change (% chg)

$-0.50 (-1.18%)
Prev Close
$42.35
Open
$42.28
Day's High
$42.62
Day's Low
$41.83
Volume
6,577,097
Avg. Vol
8,330,375
52-wk High
$46.46
52-wk Low
$34.32

Select another date:

Wed, Mar 20 2019

Photo

Pfizer buys stake in French gene therapy firm Vivet

Pfizer Inc said on Wednesday it acquired a 15 percent stake in Vivet Therapeutics, as well as an exclusive option to fully acquire it, a deal that will give it access to the French company's experimental gene therapy for a rare genetic disorder called Wilson disease.

UPDATE 1-Pfizer buys stake in French gene therapy firm Vivet

March 20 Pfizer Inc said on Wednesday it acquired a 15 percent stake in Vivet Therapeutics, as well as an exclusive option to fully acquire it, a deal that will give it access to the French company's experimental gene therapy for a rare genetic disorder called Wilson disease.

Pfizer buys stake in French gene therapy firm Vivet

March 20 Pfizer Inc said on Wednesday it has acquired a 15 percent stake in Vivet Therapeutics, and has an exclusive option to fully acquire the privately held French company that develops gene therapies for liver disorders.

FDA approves Pfizer's biosimilar to Roche's Herceptin

The U.S. Food and Drug Administration said on Monday it approved Pfizer Inc's biosimilar to Roche AG's blockbuster breast cancer treatment Herceptin.

UPDATE 1-FDA approves Pfizer's biosimilar to Roche's Herceptin

March 11 The U.S. Food and Drug Administration said on Monday it approved Pfizer Inc's biosimilar to Roche AG's blockbuster breast cancer treatment Herceptin.

FDA approves Pfizer's biosimilar to Roche's Herceptin

March 11 The U.S. Food and Drug Administration said on Monday it approved Pfizer Inc's biosimilar to Roche AG's blockbuster treatment for breast cancer, Herceptin.

Pfizer unit Meridian under civil investigation by U.S. Attorney

Pfizer Inc said on Thursday it received a request for documents as part of a U.S. investigation related to quality issues involving the manufacture of auto-injectors at its Meridian Medical Technologies site.

Pfizer unit Meridian under civil investigation by U.S. Attorney

Pfizer Inc said on Thursday it received a request for documents as part of a U.S. investigation related to quality issues involving the manufacture of auto-injectors at its Meridian Medical Technologies site.

Pfizer unit Meridian under civil investigation by U.S. Attorney

Feb 28 Pfizer Inc said on Thursday it received a request for documents as part of a U.S. investigation related to quality issues involving the manufacture of auto-injectors at its Meridian Medical Technologies site.

BRIEF-Pfizer Receives European Approval For Zirabev, A Biosimilar To Avastin

* PFIZER RECEIVES EUROPEAN APPROVAL FOR ZIRABEV (BEVACIZUMAB), A BIOSIMILAR TO AVASTIN

Select another date: